Johnson & Johnson beats Wall Street estimates, raises full-year forecast

Johnson & Johnson reported quarterly earnings that beat Wall Street estimates, driven by strong performance in its medicines division. The company also raised its full-year sales and profit forecast. The results underscore the resilience of J&J's pharmaceutical segment.